162 related articles for article (PubMed ID: 26006306)
1. The use of captisol (SBE7-β-CD) in oral solubility-enabling formulations: Comparison to HPβCD and the solubility-permeability interplay.
Beig A; Agbaria R; Dahan A
Eur J Pharm Sci; 2015 Sep; 77():73-8. PubMed ID: 26006306
[TBL] [Abstract][Full Text] [Related]
2. The interaction of nifedipine with selected cyclodextrins and the subsequent solubility-permeability trade-off.
Beig A; Miller JM; Dahan A
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1293-9. PubMed ID: 23770429
[TBL] [Abstract][Full Text] [Related]
3. Toward Successful Cyclodextrin Based Solubility-Enabling Formulations for Oral Delivery of Lipophilic Drugs: Solubility-Permeability Trade-Off, Biorelevant Dissolution, and the Unstirred Water Layer.
Fine-Shamir N; Beig A; Zur M; Lindley D; Miller JM; Dahan A
Mol Pharm; 2017 Jun; 14(6):2138-2146. PubMed ID: 28505451
[TBL] [Abstract][Full Text] [Related]
4. Head-To-Head Comparison of Different Solubility-Enabling Formulations of Etoposide and Their Consequent Solubility-Permeability Interplay.
Beig A; Miller JM; Lindley D; Carr RA; Zocharski P; Agbaria R; Dahan A
J Pharm Sci; 2015 Sep; 104(9):2941-7. PubMed ID: 25989509
[TBL] [Abstract][Full Text] [Related]
5. Polymer-free electrospun nanofibers from sulfobutyl ether
Yildiz ZI; Celebioglu A; Uyar T
Int J Pharm; 2017 Oct; 531(2):550-558. PubMed ID: 28445768
[TBL] [Abstract][Full Text] [Related]
6. Oral delivery of lipophilic drugs: the tradeoff between solubility increase and permeability decrease when using cyclodextrin-based formulations.
Beig A; Agbaria R; Dahan A
PLoS One; 2013; 8(7):e68237. PubMed ID: 23874557
[TBL] [Abstract][Full Text] [Related]
7. An ocular drug delivery system containing zinc diethyldithiocarbamate and HPbetaCD inclusion complex--corneal permeability, anti-cataract effects and mechanism studies.
Wang S; Li D; Ito Y; Liu X; Zhang J; Wu C
J Pharm Pharmacol; 2004 Oct; 56(10):1251-7. PubMed ID: 15482639
[TBL] [Abstract][Full Text] [Related]
8. Predicting the solubility-permeability interplay when using cyclodextrins in solubility-enabling formulations: model validation.
Miller JM; Dahan A
Int J Pharm; 2012 Jul; 430(1-2):388-91. PubMed ID: 22465550
[TBL] [Abstract][Full Text] [Related]
9. A win-win solution in oral delivery of lipophilic drugs: supersaturation via amorphous solid dispersions increases apparent solubility without sacrifice of intestinal membrane permeability.
Miller JM; Beig A; Carr RA; Spence JK; Dahan A
Mol Pharm; 2012 Jul; 9(7):2009-16. PubMed ID: 22632106
[TBL] [Abstract][Full Text] [Related]
10. Formulation of rifampicin-cyclodextrin complexes for lung nebulization.
Tewes F; Brillault J; Couet W; Olivier JC
J Control Release; 2008 Jul; 129(2):93-9. PubMed ID: 18514353
[TBL] [Abstract][Full Text] [Related]
11. The Solubility-Permeability Trade-Off of Progesterone With Cyclodextrins Under Physiological Conditions: Experimental Observations and Computer Simulations.
Sun L; Zhang B; Sun J
J Pharm Sci; 2018 Jan; 107(1):488-494. PubMed ID: 29031956
[TBL] [Abstract][Full Text] [Related]
12. Preparation and
Al-Heibshy FNS; Başaran E; Öztürk N; Demirel M
Drug Dev Ind Pharm; 2020 Sep; 46(9):1495-1506. PubMed ID: 32804005
[TBL] [Abstract][Full Text] [Related]
13. The solubility-permeability interplay when using cosolvents for solubilization: revising the way we use solubility-enabling formulations.
Miller JM; Beig A; Carr RA; Webster GK; Dahan A
Mol Pharm; 2012 Mar; 9(3):581-90. PubMed ID: 22280478
[TBL] [Abstract][Full Text] [Related]
14. Preferential Formulation of Second Generation Antipsychotic Asenapine as Inclusion Complex with Sulphobutylether-βCD (Captisol): In vitro and In vivo Evaluation.
Kulkarni JA; Avachat AM; Avachat CM; Pradhan R; Suryawanshi TS; Khan EM; Martis EAF; Coutinho EC; Padhye S
Curr Drug Deliv; 2018; 15(4):520-531. PubMed ID: 29165075
[TBL] [Abstract][Full Text] [Related]
15. Bioavailability and anticataract effects of a topical ocular drug delivery system containing disulfiram and hydroxypropyl-beta-cyclodextrin on selenite-treated rats.
Wang S; Li D; Ito Y; Nabekura T; Wang S; Zhang J; Wu C
Curr Eye Res; 2004 Jul; 29(1):51-8. PubMed ID: 15370367
[TBL] [Abstract][Full Text] [Related]
16. Novel formulation strategies for enhancing oral delivery of methoxyflavones in Kaempferia parviflora by SMEDDS or complexation with 2-hydroxypropyl-β-cyclodextrin.
Mekjaruskul C; Yang YT; Leed MG; Sadgrove MP; Jay M; Sripanidkulchai B
Int J Pharm; 2013 Mar; 445(1-2):1-11. PubMed ID: 23376503
[TBL] [Abstract][Full Text] [Related]
17. The solubility-permeability interplay in using cyclodextrins as pharmaceutical solubilizers: mechanistic modeling and application to progesterone.
Dahan A; Miller JM; Hoffman A; Amidon GE; Amidon GL
J Pharm Sci; 2010 Jun; 99(6):2739-49. PubMed ID: 20039391
[TBL] [Abstract][Full Text] [Related]
18. Improvement in solubility and dissolution rate of 1, 2-dithiole-3-thiones upon complexation with beta-cyclodextrin and its hydroxypropyl and sulfobutyl ether-7 derivatives.
Dollo G; Le Corre P; Chollet M; Chevanne F; Bertault M; Burgot JL; Le Verge R
J Pharm Sci; 1999 Sep; 88(9):889-95. PubMed ID: 10479350
[TBL] [Abstract][Full Text] [Related]
19. Hot-melt extrusion as a continuous manufacturing process to form ternary cyclodextrin inclusion complexes.
Thiry J; Krier F; Ratwatte S; Thomassin JM; Jerome C; Evrard B
Eur J Pharm Sci; 2017 Jan; 96():590-597. PubMed ID: 27687637
[TBL] [Abstract][Full Text] [Related]
20. Cyclodextrin-containing poly(ethyleneoxide) tablets for the delivery of poorly soluble drugs: potential as buccal delivery system.
Cappello B; De Rosa G; Giannini L; La Rotonda MI; Mensitieri G; Miro A; Quaglia F; Russo R
Int J Pharm; 2006 Aug; 319(1-2):63-70. PubMed ID: 16650700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
